Microbot Medical has partnered with Baptist Hospital of Miami for its pivotal human clinical trial of Liberty. Credit: MAD.vertise via Shutterstock.

Microbot Medical has announced the Baptist Hospital of Miami, US, as the second site taking part in the human clinical trial of its Liberty robotic system. 

The Liberty robotic system, which secured US Food and Drug Administration (FDA) clearance last month, is a single-use endovascular system which aims to increase procedure efficiency. It integrates advanced robotic systems with intuitive control mechanisms, offering surgeons improved dexterity and accuracy. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Baptist Hospital of Miami, which includes Miami Cardiac & Vascular Institute and Miami Cancer Institute, is the second site announced by Microbot. This follows an announcement last month that the medtech company had partnered with Brigham and Women’s Hospital in Boston, Massachusetts, as its first site for the clinical trial.  

In December 2023, Microbot completed a pre-clinical study of the Liberty system, where three interventional radiologists performed 96 robotic navigations. The study included a microscopic evaluation of target vessels and surrounding tissues after using various commercially available intravascular catheters controlled by Liberty. Endovascular surgery is a minimally invasive procedure that uses catheters to access blood vessels for the treatment of vascular diseases. 

In June 2023, Microbot secured NIS1.62m ($440,000) in funding from the Israel Innovation Authority to further develop its manufacturing process for the Liberty system. 

The surgical robotics space continues to make waves in the medtech sector. In February 2024, Virtual Incision’s MIRA surgical robot system secured FDA clearance for adult colectomy procedures. Earlier that month, the system began its journey to the International Space Station (ISS) to test the limits of remote surgical robotics.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to GlobalData, the surgical robotics market is projected to reach $10bn globally by the end of 2024, growing to $15.8bn by 2030. One of the reasons for this growth is increasing demand from the growing elderly population seeking less invasive and precise surgical options, according to GlobalData Medical Analyst Graysen Vigneux. 

Microbot’s CEO Harel Gadot said: “We believe the interest in the Liberty technology is overwhelming, as evident by the fast pace of enrolling and activating leading sites into the pivotal trial since we announced the IDE. We are excited for our partnership with Baptist Hospital of Miami, which is one of the leading hospitals in the United States.”